Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.87 |
| ▸ | USP2 | O75604 | 3/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.87 |
| ▸ | RECQL | P46063 | 2/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | LCK | P06239 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | ALPI | P09923 | 1/20 | 0.71 |
| ▸ | XIAP | P98170 | 1/20 | 0.71 |
| ▸ | KDM6B | O15054 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL27642065 | 1.00 | SLC7A5 (0.87) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL8579019 | 0.95 | SLC7A5 (0.79) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL8579024 | 0.95 | SLC7A5 (0.79) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL245057 | 0.95 | SLC7A5 (0.90) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL28214733 | 0.95 | SLC7A5 (0.90) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL245058 | 0.95 | SLC7A5 (0.90) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL27841673 | 0.95 | SLC7A5 (0.96) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL704089 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL116907 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL20582239 | 0.93 | SLC7A5 (1.00) | SLC7A5USP2PTGS1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871818-B2 | Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI | 2011-08-04 | — | — | US | disclosed |
| US-20090048350-A1 | GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER AND ITS PREPARING METHOD | Tsuji, Akira (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080119568-A1 | Adding pH-sensitive polymethacrylic acid; side effect reduction | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-05-22 | — | — | US | disclosed |
| US-20060121107-A1 | Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1588715-A1 | AGENT IMPROVING PROTON-DRIVEN TRANSPORTER-MEDIATED ABSORPTION IN DIGESTIVE TRACT AND PROCESS FOR PRODUCING THE SAME | Tsuji, Akira (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | SLC7A5 3832/4885USP2 3710/4885PTGS1 4036/4885 |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | SLC7A5 3806/4885USP2 3768/4885PTGS1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.